1. Home
  2. TECX vs VALU Comparison

TECX vs VALU Comparison

Compare TECX & VALU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc.

TECX

Tectonic Therapeutic Inc.

HOLD

Current Price

$18.42

Market Cap

359.0M

Sector

N/A

ML Signal

HOLD

Logo Value Line Inc.

VALU

Value Line Inc.

N/A

Current Price

$37.55

Market Cap

340.4M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
TECX
VALU
Founded
2019
1931
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
359.0M
340.4M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
TECX
VALU
Price
$18.42
$37.55
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$81.20
N/A
AVG Volume (30 Days)
301.7K
3.1K
Earning Date
11-06-2025
12-15-2025
Dividend Yield
N/A
3.42%
EPS Growth
N/A
6.17
EPS
N/A
2.26
Revenue
N/A
$34,801,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$16.85
Revenue Growth
N/A
N/A
52 Week Low
$13.70
$32.94
52 Week High
$61.07
$55.01

Technical Indicators

Market Signals
Indicator
TECX
VALU
Relative Strength Index (RSI) 45.34 54.29
Support Level $18.60 $37.07
Resistance Level $20.62 $39.20
Average True Range (ATR) 1.46 0.81
MACD -0.22 0.23
Stochastic Oscillator 5.03 65.88

Price Performance

Historical Comparison
TECX
VALU

About TECX Tectonic Therapeutic Inc.

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About VALU Value Line Inc.

Value Line Inc is a U.S based company. It produces investment periodicals based on underlying research and making available copyright data, including ranking system and other information, to third parties under written agreements for use in third-party managed and marketed investment products and for other purposes. The company markets under brands including Value Line, the Value Line logo, The Value Line Investment Survey, Smart Research, Smarter Investing and a trusted name in Investment Research. Its only operating segment being Publishing.

Share on Social Networks: